secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2023-06-27T23:59:59+00:00
Accession:  0001420720-23-000033
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio appoints Martin Brenner as permanent CEO and Felipe Duran as permanent CFO
-------------------------------------------------------------------------------

- Martin Brenner, formerly interim CEO and CSO, appointed permanent CEO; Felipe Duran, formerly interim CFO, appointed permanent CFO, effective June 22, 2023.
- Brenner's base salary set at $507,150, including prior $7,500/month interim stipend; granted 75,833 RSUs vesting over 7 months.
- Duran's compensation unchanged: base salary of $350,000 with 40% target bonus and $140,000 special incentive bonus.
- Board expresses confidence in duo to lead iBio's AI-powered antibody discovery platform and next stage of growth.
- Brenner has leadership experience at major pharma including Pfizer and Merck; Duran previously VP of FP&A at iBio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072023000033/0001420720-23-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072023000033/ibio-20230622x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-23-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer